Wegovy and Eye Damage: What the Evidence Shows

You read the headline. Here's the fuller picture.

A 2024 study published in the journal JAMA Ophthalmology described cases of non-arteritic anterior ischaemic optic neuropathy (NAION) in people taking semaglutide. NAION is a condition where blood flow to the optic nerve is disrupted, causing sudden, usually painless vision loss in one eye. The study drew significant media attention, and understandably so.

What the headlines often skipped: the study was observational, not a randomised trial. It could identify an association but not establish that semaglutide caused NAION. NAION itself is rare in the general population, and several of the affected individuals had pre-existing risk factors, including sleep apnoea, small optic disc anatomy and cardiovascular disease, that are independently associated with the condition. Regulatory bodies, including the MHRA, reviewed the signal. As of mid-2026 NAION is listed as a potential risk under ongoing monitoring, but a definitive causal link has not been established. The MHRA's Yellow Card scheme continues to collect reports so that the evidence base can mature.

A question our prescribers hear most weeks is whether this risk applies to everyone. It doesn't appear to. Current evidence points most clearly at people who already have risk factors for optic nerve problems, and at a higher-dose range. Healthy eyes and no relevant history reduce, though never eliminate, the concern. That's exactly why a full medical history is central to any legitimate clinical review before a prescription is issued.

The diabetic retinopathy complication: a separate, better-understood risk

For people with type 2 diabetes, there is a distinct and longer-established eye concern: rapid improvement in blood-glucose control can cause a temporary worsening of diabetic retinopathy, the damage that persistently high sugar causes to tiny retinal vessels. This is not unique to semaglutide; it has been observed with other glucose-lowering treatments and is thought to reflect the retina adjusting to a faster-than-expected change in its chemical environment.

In the SUSTAIN-6 cardiovascular trial, more participants on semaglutide experienced retinopathy complications than those on placebo, though the absolute numbers were small and the trial was not designed to study this. If you have a diagnosis of diabetic retinopathy, this is an important conversation to have with your prescriber and your ophthalmologist before starting any GLP-1 medicine. It does not automatically rule treatment out, but it shapes how closely your vision should be monitored. You can read more about the specific retinal concerns on our semaglutide and eyesight page.

Wegovy is licensed for weight management in adults, and the NHS semaglutide page summarises the known side-effect profile including the signal around vision changes. It's a sensible first stop if you want the regulatory-approved patient information in plain language.

What symptoms should prompt urgent action

Sudden or unexplained vision changes are always worth taking seriously, whether or not you are on any medicine. If you experience sudden blurring, partial loss of vision, double vision, or any change that feels abrupt rather than gradual, seek same-day medical attention. Don't wait for your next routine appointment. For slower, progressive changes (mild blurring that develops over weeks, for instance) book a GP or optician appointment rather than attending A&E, but don't dismiss it either.

Other eye-related topics that come up in this area include the reported link between semaglutide and eye stroke, which relates to the optic nerve vascular mechanism above, and questions about intraocular pressure changes on Wegovy. Some people also report eye twitching during treatment, though this is generally considered unrelated to the serious optic events. The mechanisms differ and the evidence quality varies considerably between them.

If you want the broader context of how semaglutide works and what the full side-effect landscape looks like, that's covered in detail separately. The cost and practicalities of starting treatment are set out on our weight-loss treatment overview if that's useful background.

How this is handled at the clinical assessment stage

A legitimate clinical review before prescribing Wegovy will ask about your eye health history. Relevant flags include a diagnosis of diabetic retinopathy, a previous episode of NAION, significant sleep apnoea, a history of cardiovascular disease affecting small vessels, and any current unexplained visual symptoms. Disclosing these honestly matters, not because they are automatic barriers, but because they inform how the prescriber weighs benefits against risks for you specifically.

At nume, every consultation is reviewed by a GPhC-registered Independent Prescriber. A real clinician reads your answers; the decision is theirs to make. If your history suggests your eyes warrant closer monitoring, the prescriber may recommend that you discuss treatment with your GP or ophthalmologist first. That's the right call, not a bureaucratic one. You can explore whether treatment is appropriate for your situation by starting a free consultation, with no obligation to proceed. Our Wegovy treatment page covers what a standard assessment looks like from start to prescription.